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Introduction {#sec001}
============

Ceftiofur, a third generation cephalosporin, is one of the most common antimicrobials administered to feedlot cattle and lactating dairy cows in the United States for treatment of respiratory disease, \[[@pone.0223378.ref001],[@pone.0223378.ref002]\] metritis, \[[@pone.0223378.ref003]\] and is also used in an extralabel manner to treat enteric disease \[[@pone.0223378.ref004]\]. This use has led to widespread concern over selection for bacteria with antimicrobial resistance (AMR) in the feces of treated cattle that could be transferred to humans through the food chain \[[@pone.0223378.ref005]\]. To determine this risk, studies have determined the presence of AMR genes in dairy cattle feces immediately after ceftiofur treatment \[[@pone.0223378.ref006]\], tested the susceptibility of *E*. *coli* isolates from preweaned calves and cows on farms that use ceftiofur \[[@pone.0223378.ref007],[@pone.0223378.ref008]\], and quantified *bla(CMY-2)* and/or *bla(CTX-M)* in feedlot steers \[[@pone.0223378.ref009]--[@pone.0223378.ref012]\] and dairy cattle \[[@pone.0223378.ref013]\] treated with ceftiofur. Due to the variability in the populations studied and the outcome measures, the conclusions of these studies have varied widely, precluding any clear recommendations for prudent use of ceftiofur in cattle.

Further complicating the association between ceftiofur use and AMR outcomes is the availability of different drug formulations, which varied across previous studies. Ceftiofur hydrochloride (CHCL) is a 50 mg/ml oil-based suspension that is FDA-approved for daily administration for 3--5 days at 1.1--2.2 mg/kg by subcutaneous or intramuscular route. Cattle cannot be slaughtered for human consumption within 4 days of the last treatment with CHCL (Zoetis). Ceftiofur crystalline-free acid (CCFA) is a 200 mg/ml oil-based suspension that is administered as single-dose therapy at 6.6 mg/kg with a meat withdrawal time of 14 days. Due to the slow-release formulation, CCFA must be administered subcutaneously on the posterior aspect of the ear or at the base of the ear (Zoetis). Some producers may use CHCL because of the shorter withdrawal time and easier route of administration, while others may prefer CCFA due to the ease of single-dose therapy. Although both products are FDA-approved for similar conditions in cattle and used somewhat interchangeably, they produce different exposure profiles, which could affect selection of antibiotic-resistant bacteria. To our knowledge, a comparison of the effect of these formulations on AMR in fecal bacteria of treated cattle has not been performed.

We hypothesize that the concentration of antimicrobials within the gastrointestinal tract (GIT) is significantly associated with the risk of AMR in fecal bacteria as measured by an increase in MIC. Surprisingly, this association remains unknown because it has been difficult to directly obtain intestinal drug concentration data. We showed in our previous studies that continuous collection of luminal fluid from ileum and colon is possible, and allowed for measurement of drug concentrations in intestinal fluid and pharmacokinetic modelling of the active drug concentrations during the time after drug injection \[[@pone.0223378.ref014]--[@pone.0223378.ref016]\]. The objective of the current study was to compare the active antimicrobial concentrations in the GIT of steers treated with either CHCL or CCFA, and correlate those concentrations with changes in fecal bacteria, including changes in the minimum inhibitory concentration of ceftiofur in *E*. *coli*. In addition to serving as indicator organism for foodborne pathogens, *E*. *coli* has human health importance and can acquire relevant resistance to third-generation cephalosporins.

Materials and methods {#sec002}
=====================

Animals and treatments {#sec003}
----------------------

This study was approved by the North Carolina State University Institutional Animal Care and Use Committee (protocol \# 18-020A). This study took place May through July of 2016. Twelve six-month-old Holstein steers (186 to 288 kg) were obtained from the North Carolina State University Dairy Educational Unit as was done in previous studies \[[@pone.0223378.ref015],[@pone.0223378.ref017]--[@pone.0223378.ref019]\]. Sample size was determined based on the number needed for appropriate pharmacokinetic modeling from our previous studies in cattle \[[@pone.0223378.ref014],[@pone.0223378.ref015],[@pone.0223378.ref019]\]. Investigators were not blinded to the treatment groups of the steers. Steers were fitted for placement of ultrafiltration probes in the ileum and spiral colon as described below. At 24--48 hours post-probe placement, animals received one of two treatments (n = 6 steers per treatment)---subcutaneous injection of ceftiofur crystalline-free acid (CCFA; Excede^®^; 6.6 mg/kg) as a single dose at the base of the ear, or ceftiofur hydrochloride (CHCL; Excenel^®^; 2.2 mg/kg) subcutaneously in the neck every 24 hours for 3 treatments. Using a parallel study design, all procedures and sample collection with CCFA steers were completed first, and then treatment and sampling of CHCL steers were completed, so steers were not randomly allocated to treatment groups. Steers were housed in pairs that received the same treatment in stalls bedded with shavings and were fed grass hay with free access to water for the duration of the study. At the conclusion of the study and observation of the appropriate meat withdrawal time, all ultrafiltration probes and catheters were removed, and the steers were sold.

Plasma collection {#sec004}
-----------------

Prior to drug administration, a jugular catheter (Intracath®, Becton Dickinson, Franklin Lakes, NJ) was inserted into the jugular vein. Blood samples (6 ml) were collected in lithium heparin tubes at appropriate intervals for optimum pharmacokinetic modeling of each drug for at least 3 drug half-lives, accounting for 90% of drug elimination from the plasma. These were time 0, 15 min, 30 min, 1, 2, 4, 8, 12, 24, 32, 48, 72, 96, 120, 144, 168, 192 hours for CCFA and time 0, 15 min, 30 min, 1, 2, 4, 8, 12, 24, 25, 26, 28, 30, 32, 36, 48, 48.25, 48.5, 49, 50, 52, 54, 56, 60, 72, 74, 78, 96 hr after the initial dose for CHCL. The tubes were immediately centrifuged at 1,000 x g for 10 minutes to collect plasma and stored at -80°C until assayed.

Placement of intestinal ultrafiltration probes {#sec005}
----------------------------------------------

Surgical procedures took place over 4 days with 3 surgeries per day as previously described \[[@pone.0223378.ref016]\] with the following variation in the anesthesia procedure. Briefly, food and water were withheld from all steers for 12 hours prior to surgery. The steers were restrained standing in a conventional chute. The right flank was anesthetized by infiltration of 2% lidocaine dorsally and ventrally to the lateral vertebral processes of L1-L4 (approximately 80 ml per steer). After entering the abdomen, the ileum and colon were identified by first retracting the cecum through the flank incision. The collecting loops of an ultrafiltration probe (UF-3-12, BAS; Bioanalytical Systems, West Lafayette, IN, USA) were inserted into the lumen of the ileum and spiral colon, and sutured into place. The free ends of the probes were exteriorized cranial to the skin incision. The calves received 2 mg/kg of flunixin meglumine intravenously prior to surgery and 24 hours after surgery according to the IACUC protocol. There is no evidence of any impact on ceftiofur pharmacokinetics due to flunixin administration \[[@pone.0223378.ref020]\].

Gastrointestinal fluid collection {#sec006}
---------------------------------

After surgery, the probes were prepared to collect samples of fluid from the ileum and spiral colon of each animal. The tubing exiting the body cavity was connected to a needle within a vacuum vial needle holder using flexible tubing and secured. The vial holder was sutured to the skin over the transverse processes of the lumbar spine using 2--0 nylon (Ethicon; Somerville, NJ) and white tape butterfly tags. To collect the ultrafiltrate, a 3-ml evacuated tube with no additive (Becton-Dickinson) was inserted onto the needle of the vacuum vial needle holder. The ultrafiltrate collected is free of protein and other intestinal contents that could potentially bind to the antibiotic. Drug administration and sample collection began 24--48 hours after surgery. Steers were allowed free-choice grass hay and water after recovery from surgery until the completion of the study. Samples from probes placed in the ileum and spiral colon were collected 0, 2, 4, 8, 12, 24, 32, 48, 72, 96, 120, 144, 168, and 192 hours post administration of CCFA and 0, 2, 4, 6, 8, 12, 24, 26, 28, 30, 32, 36, 48, 50, 52, 54, 56, 60, 72, 74, 78, and 96 hours post administration of initial CHCL dose by changing the tubes at the predetermined time points.

Interstitial fluid collection {#sec007}
-----------------------------

An *in-vivo* ultrafiltration probe was also inserted in the subcutaneous space above the shoulders in a manner described in previous studies (Davis et al., 2007; Messenger et al., 2012). The interstitial fluid (ISF) was collected at time 0 (pre-treatment) and at the same time points as for the GI fluid collection. The collected fluid was immediately frozen at -80°C for further analysis.

Determining active drug concentration {#sec008}
-------------------------------------

Plasma and tissue fluid samples were analyzed by reverse-phase high pressure liquid chromatography (HPLC) with ultraviolet detection to determine the active concentrations of ceftiofur and its metabolites as previously described \[[@pone.0223378.ref021],[@pone.0223378.ref022]\]. Ceftiofur is rapidly metabolized to the active metabolite desfuroylceftiofur in cattle, which is the predominant metabolite responsible for antibacterial effects. The assay converts all ceftiofur and desfuroylceftiofur conjugates to a single stable derivative, desfuroylceftiofur acetamide, which is measured by HPLC ultraviolet detection. All drug concentrations were determined from calibration curves made from fortified (spiked) blank plasma, intestinal and interstitial fluid collected from the experimental calves prior to antibiotic administration. Calibration curves were prepared from fortifying the blank matrix with reference drug standards of ceftiofur (United States Pharmacopeia {USP}, Rockville, MD) to validate the HPLC analysis and perform Quality Control (QC) assessments during the assay.

Pharmacokinetic analysis {#sec009}
------------------------

The drug concentrations were analyzed using standard pharmacokinetic methods to examine the drug disposition for each calf. A computer program (Phoenix® WinNonlin®, V. 8.0; Pharsight Corporation, Certara, St. Louis MO) was used to determine pharmacokinetic (PK) parameters.

Plasma, ISF, and intestinal drug concentrations were plotted on linear and semi-logarithmic graphs for analysis and for visual assessment of the best model for pharmacokinetic analysis. Specific models (e.g., one, two, etc. compartments) were determined on the basis of visual analysis for goodness of fit and by visual inspection of residual plots. The best model fit was based on the equation described in the following formula: $$\text{C} = \frac{\text{k}01\text{FD}}{\text{V}\left( {\text{k}01 - \text{k}10} \right)}\left( {\text{e}^{- \text{k}10\text{t}} - \text{e}^{- \text{k}01\text{t}}} \right)$$ Where C is the plasma concentration, t is time, k~01~ is the non-IV absorption rate, assuming first-order absorption, k~10~ is the elimination rate constant, V is the apparent volume of distribution, F is the fraction of drug absorbed, and D is the non-IV dose. Secondary parameters calculated from the model included the peak concentration (C~MAX~), time to peak concentration (T~MAX~), area under the plasma-concentration vs time profile (AUC), and the respective absorption and terminal half-lives (t½).

A compartmental model could not be fit to all of the concentrations from the intestinal fluid samples because of sparse sampling (incomplete collection) in some calves. Therefore, data from some calves were analyzed using noncompartmental analysis (NCA) in the same pharmacokinetic program described above. For the NCA, the area under the plasma concentration vs time curve (AUC) from time 0 to the last measured concentration, (defined by the limit of quantification) was calculated using the log-linear trapezoidal method. The AUC from time 0 to infinity was calculated by adding the terminal portion of the curve, estimated from the relationship C~n~/ λ~Z~, to the AUC~0\ Cn~, where λ~Z~ is the terminal slope of the curve, and C~n~ is the last measured concentration point.

The relative drug transfer from the plasma compartment to the ISF and intestinal fluids was measured by calculation of a *penetration factor*. The penetration factor was determined by the ratio of AUC for the intestinal fluid to the AUC for plasma: $$\text{Penetration}\ \text{Factor} = \frac{\text{AUC}_{\text{Intestinal}\ \text{fluid}\ \text{or}\ \text{ISF}}}{\text{AUC}_{\text{Plasma}}}$$

Fecal sampling {#sec010}
--------------

Individual fecal samples (\>50 g) from each steer were manually collected from the rectum using a clean rectal sleeve and sterile lubricant immediately prior to treatment, and at 24, 36, and 48 hours after treatment. Following this period, fecal samples were collected approximately every day through 7 days and again at 14 days after drug administration.

Quantification of *E*. *coli* from feces {#sec011}
----------------------------------------

One gram of feces was inoculated into 9 ml EC broth (Oxoid Ltd., Basingstoke, Hampshire, England) and vortexed. One ml was immediately removed and serially diluted ten-fold in sterile phosphate-buffered saline, and 100 μl was plated in triplicate onto HardyCHROM^TM^ ECC Media (Hardy Diagnostics, Santa Maria, CA). Plates were incubated overnight at 37°C and dilutions that yielded between 30 and 300 pink-violet colonies on each of the 3 plates were counted and counts were averaged to determine the concentration (CFU/g) of *E*. *coli* at each time point. The remaining EC broth was incubated overnight at 37°C, and if no growth was observed on direct plates, the enrichment was streaked for isolation on ECC plates and incubated overnight at 37°C. From the quantified or enrichment plate, eight colonies were randomly picked, streaked onto Columbia agar with 5% sheep blood (Remel, Lenexa, KS) and incubated overnight at 37°C. Following incubation, each isolate was transferred to a 2-ml cryogenic vial containing LB Broth (Sigma-Aldrich, St. Louis, MO) supplemented with 25% glycerol, vortexed, and frozen at -80°C.

Determination of minimum inhibitory concentration {#sec012}
-------------------------------------------------

The minimum inhibitory concentration (MIC) of ceftiofur for each *E*. *coli* isolate was determined using a broth microdilution method and following Clinical and Laboratory Standards Institute standards \[[@pone.0223378.ref023]\]. Isolates were grown overnight on blood agar. A single colony was inoculated into 3 ml of sterile phosphate-buffered saline and brought to a 0.5 McFarland Standard, then 10 μl of this Standard were further diluted in 990 μl sterile phosphate-buffered saline. This final bacterial suspension (50 μl) was inoculated into 50 μl of two-fold serial dilutions of ceftiofur (USP, Rockville, MD) in Mueller Hinton broth (BD, Sparks, MD) ranging in concentration from 0.03 to 32 mg/L. Each bacterial suspension (50 μl) was also inoculated into a control well containing 50 μl Mueller Hinton broth (BD, Sparks, MD), with no antibiotic. The 96-well plates were incubated 18 hours at 37°C. The drug concentration in the first well with no visible growth was determined to be the MIC.

DNA extraction and 16S rRNA gene sequencing {#sec013}
-------------------------------------------

Fresh feces collected at each time point were frozen in 1 gram aliquots for future analysis. From these samples, 50 mg of feces were extracted individually using a MoBio PowerMag Microbiome kit (Qiagen, Inc., Germanton, MD) optimized for the epMotion 5075 TMX (Eppendorf, Hauppauge, NY). The DNA libraries were prepared as described previously \[[@pone.0223378.ref024]\].

Illumina MiSeq sequencing of bacterial communities {#sec014}
--------------------------------------------------

The V4 region of the 16S rRNA gene was amplified from each sample using the Dual indexing sequencing strategy \[[@pone.0223378.ref025]\]. Sequencing was done on the Illumina MiSeq platform, using a MiSeq Reagent Kit V2 500 cycles (2 x 250bp) (Illumina cat\# MS102-2003), according to the manufacturer\'s instructions with modifications \[[@pone.0223378.ref025]\]. Accuprime High Fidelity Taq (Life Technologies cat \# 12346094) was used. PCR was performed using the conditions (Standard or Touch Down) shown by Seekatz \[[@pone.0223378.ref024]\]. If additional template was used, the water volume was changed accordingly. PCR products were visualized using an E-Gel 96 with SYBR Safe DNA Gel Stain, 2% (Life technologies cat\# G7208-02). Libraries were normalized using SequalPrep Normalization Plate Kit (Life technologies cat \#A10510-01) following the manufacturer's protocol for sequential elution. The concentration of the pooled samples was determined using Kapa Biosystems Library Quantification kit for Illumina platforms (KapaBiosystems KK4824). The sizes of the amplicons in the library were determined using the Agilent Bioanalyzer High Sensitivity DNA analysis kit (cat\# 5067--4626). The final library consisted of equal molar amounts from each of the plates, normalized to the pooled plate at the lowest concentration. Sequencing libraries were prepared according to Illumina's protocol for Preparing Libraries for Sequencing on the MiSeq (part\# 15039740 Rev. D) for 2 nM or 4 nM libraries. If the library concentration was below 1 nM, an alternative method was used for denaturation \[[@pone.0223378.ref026]\]. PhiX and genomes were added in 16S amplicon sequencing to create diversity. Sequencing reagents were prepared according to the Schloss SOP \[[@pone.0223378.ref025]\], and custom read 1, read 2 and index primers were added to the reagent cartridge. FASTQ files were generated for paired end reads.

Microbiota analysis {#sec015}
-------------------

Analysis of the V4 region of the 16S rRNA gene was performed using the DADA2 method for the inference of exact amplicon sequence variants (ASVs) \[[@pone.0223378.ref027],[@pone.0223378.ref028]\]. Our analysis protocol generally followed the DADA2 tutorial (<https://benjjneb.github.io/dada2/tutorial.html>). Samples were filtered based on a maximum expected error threshold of 2. ASVs were inferred using the dada function with default parameters except that samples were pooled in order to increase sensitivity to rare sequence variants. Chimeras were removed using the default consensus removal method \[[@pone.0223378.ref027]\]. Taxonomy was assigned using the implementation of the naive Bayesian classifier available in the dada2 R package, and the Silva v128 reference database \[[@pone.0223378.ref029],[@pone.0223378.ref030]\].

Statistical analysis {#sec016}
--------------------

Mean pharmacokinetic parameters were compared using a Student's t test. Mean *E*. *coli* concentration was compared over time using one-way analysis of variance with the Holm-Sidak method for comparison of individual time points to time 0 \[[@pone.0223378.ref031],[@pone.0223378.ref032]\] (SigmaPlot 14.0, Systat Software Inc., San Jose, CA). Descriptive statistics (mean, median, standard deviation, and range) for MIC were computed overall, by treatment and by time point. The dependent variable consisted of the MIC values of isolates (up to 8 isolates per sample and per time point) and independent variables included treatment (CHCL vs CCFA), time point (0, 24, 36, 48, 60, 72, 96, 120, 168, 240, and 336 hours) and a two-way interaction term between treatment and time point. Several family distributions and transformations of the outcome were modeled including normal, lognormal, tobit, poisson, and negative binomial. After checking assumptions, model fit was assessed using information criteria (AIC, BIC) and residual plots. The effect of treatment and time period on MICs (log10-based transformed) was estimated using generalized linear mixed models (GLMMs) fitted with a Gaussian distribution, identity link, residual pseudo-likelihood, Newton-Raphson with ridging optimization and Kenward Rogers adjustment for denominator degrees of freedom using Proc Glimmix in SAS (SAS 9.4, SAS Institute Inc., Cary, NC). A random intercept for animal and an unstructured covariance structure were included to account for the design structure of the study (isolates nested within samples (animals) and repeated measures at the animal level). Model assumptions were tested and residuals were investigated using graphical tools. Mean MIC values and their 95% confidence intervals were computed by drug and sample time. P-values \< 0.05 were considered statistically significant. The Tukey-Kramer procedure was used to prevent inflation of Type I error due to multiple comparisons \[[@pone.0223378.ref033],[@pone.0223378.ref034]\].

Results {#sec017}
=======

Pharmacokinetic modeling {#sec018}
------------------------

The values for pharmacokinetic parameters for both CHCL and CCFA are presented in [Table 1](#pone.0223378.t001){ref-type="table"}. Because of the slow release of ceftiofur from CCFA, the maximum concentrations (C~MAX~) of ceftiofur and metabolites in the plasma were significantly lower than from injection of CHCL ([Fig 1](#pone.0223378.g001){ref-type="fig"}; P = 0.01), while the T~MAX~ (P\<0.001), half-life (P\<0.001), and AUC (P\<0.001) were greater for steers receiving CCFA. Low drug concentrations in the GIT were noted over a longer time as the half-life of ceftiofur and metabolites were 2--3 times greater in the ileum and colon for CCFA than for CHCL, but due to the variability between animals this difference was not statistically significant. Similarly, the T~MAX~ was later in both the ileum and colon of CCFA treated calves, although this difference was only significant in the colon (P = 0.03). The penetration of ceftiofur and metabolites into the ileum and colon were similar for both drugs at approximately 20% of plasma AUC. The penetration of CCFA into the ISF was significantly higher for CCFA (86 ± 62%) compared to CHCL (24 ± 16%; P = 0.009).

![Total concentration of ceftiofur equivalents in plasma, interstitial fluid (ISF), ileum, and colon for steers treated with (A) ceftiofur crystalline free acid (CCFA) and (B) ceftiofur hydrochloride (CHCL).](pone.0223378.g001){#pone.0223378.g001}

10.1371/journal.pone.0223378.t001

###### Pharmacokinetic parameters for ceftiofur crystalline free acid (CCFA) and ceftiofur hydrochlroide (CHCL) in the plasma, interstitial fluid (ISF), ileum and colon of steers.

![](pone.0223378.t001){#pone.0223378.t001g}

  ----------------- ---------------------------------------------- ------------------------------------------- ------------- --------- ---------------- ---------------------------------------------- -------------------------------------------- ------------- ---------
  **CCFA Plasma**   **CHCL Plasma**                                                                                                                                                                                                                               
  **Parameter**     **Units**                                      **Mean**                                    **Std Dev**   **CV%**   **Parameter**    **Units**                                      **Mean**                                     **Std Dev**   **CV%**
  AUC               hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   182.26                                      22.97         12.60     AUC              hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   61.63[\*](#t001fn002){ref-type="table-fn"}   11.63         18.88
  C~MAX~            ug/ml                                          1.80                                        0.95          52.70     C~MAX~           ug/mL                                          3.29[\*](#t001fn002){ref-type="table-fn"}    0.74          22.43
  k01               1/hr                                           0.26                                        0.10          37.50     k01              1/hr                                           0.53                                         0.45          84.82
  Absorption T½     hr                                             3.07                                        1.16          37.81     Absorption T½    hr                                             1.80[\*](#t001fn002){ref-type="table-fn"}    0.74          40.92
  k10               1/hr                                           0.01                                        0.01          49.66     k10              1/hr                                           0.08[\*](#t001fn002){ref-type="table-fn"}    0.01          12.30
  Elimination T½    hr                                             73.25                                       33.54         45.79     Elimination T½   hr                                             8.79[\*](#t001fn002){ref-type="table-fn"}    1.12          12.79
  T~MAX~            hr                                             14.13                                       4.56          32.25     T~MAX~           hr                                             4.98[\*](#t001fn002){ref-type="table-fn"}    1.51          30.23
  **CCFA ISF**      **CHCL ISF**                                                                                                                                                                                                                                  
  **Parameter**     **Units**                                      **Mean**                                    **Std Dev**   **CV%**   **Parameter**    **Units**                                      **Mean**                                     **Std Dev**   **CV%**
  AUC infinity      hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   91.54                                       35.98         39.31     AUC_TAU          hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   12.26                                        11.61         94.66
  AUC 0 to Cn       hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   90.81                                       28.50         31.39     AUC infinity     hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   73.32                                        84.09         114.68
  C~MAX~            ug/ml                                          1.62                                        0.61          37.68     AUC 0 to Cn      hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   43.36[\*](#t001fn002){ref-type="table-fn"}   35.24         81.28
  Half-life         hr                                             NA                                          NA            NA        C~AVE~           ug/ml                                          0.51                                         0.48          94.66
  Lambda z          1/hr                                           NA                                          NA            NA        C~MAX~           ug/ml                                          0.72[\*](#t001fn002){ref-type="table-fn"}    0.61          83.88
  MRT               hr                                             NA                                          NA            NA        C~MIN~           ug/ml                                          0.40                                         0.48          119.17
  T~MAX~            hr                                             76.67                                       65.99         86.07     Half-life        hr                                             NA                                           NA            NA
  Penetration                                                      0.86                                        0.62          71.44     Lambda z         1/hr                                           NA                                           NA            NA
                    MRT                                            hr                                          NA            NA        NA                                                                                                                         
  T~MAX~            hr                                             5.00                                        4.69          93.81                                                                                                                                
  Penetration                                                      0.24[\*](#t001fn002){ref-type="table-fn"}   0.16          65.59                                                                                                                                
  **CCFA Ileum**    **CHCL Ileum**                                                                                                                                                                                                                                
  **Parameter**     **Units**                                      **Mean**                                    **Std Dev**   **CV%**   **Parameter**    **Units**                                      **Mean**                                     **Std Dev**   **CV%**
  AUC infinity      hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   55.19                                       6.86          12.43     AUC_TAU          hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   13.82                                        9.27          67.08
  AUC 0 to Cn       hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   27.67                                       7.36          26.59     AUC infinity     hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   62.98                                        21.22         33.70
  C~MAX~            ug/ml                                          0.54                                        0.16          30.37     AUC 0 to Cn      hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   39.05                                        19.70         50.43
  Half-life         hr                                             127.74                                      16.46         12.89     C~AVE~           ug/mL                                          0.58                                         0.39          67.08
  Lambda z          1/hr                                           0.01                                        0.00          12.16     C~MAX~           ug/mL                                          1.20                                         1.00          82.75
  MRT               hr                                             192.91                                      36.54         18.94     C~MIN~           ug/mL                                          0.06                                         0.10          154.92
  T~MAX~            hr                                             45.33                                       61.12         134.82    Half-life        hr                                             66.27                                        79.51         119.97
  Penetration                                                      0.20                                        0.07          37.79     Lambda z         1/hr                                           0.06                                         0.06          97.53
                    MRT                                            hr                                          204.42        175.78    85.99                                                                                                                      
  T~MAX~            hr                                             8.33                                        4.80          57.63                                                                                                                                
  Penetration                                                      0.23                                        0.10          44.87                                                                                                                                
  **CCFA Colon**    **CHCL Colon**                                                                                                                                                                                                                                
  **Parameter**     **Units**                                      **Mean**                                    **Std Dev**   **CV%**   **Parameter**    **Units**                                      **Mean**                                     **Std Dev**   **CV%**
  AUC infinity      hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   53.34                                       43.33         81.22     AUC ~TAU~        hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   12.07                                        8.09          67.00
  AUC 0 to Cn       hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   32.38                                       28.26         87.27     AUC infinity     hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   41.09                                        25.25         61.46
  C~MAX~            ug/ml                                          0.44                                        0.24          54.82     AUC 0 to Cn      hr[\*ug](#t001fn002){ref-type="table-fn"}/ml   27.21                                        11.25         41.36
  Half-life         hr                                             94.85                                       39.34         41.47     C~AVE~           ug/ml                                          0.50                                         0.34          67.00
  Lambda z          1/hr                                           0.01                                        0.01          64.74     C~MAX~           ug/ml                                          1.55                                         2.07          133.04
  MRT               hr                                             144.43                                      55.28         38.27     C~MIN~           ug/ml                                          0.02                                         0.03          137.15
  T~MAX~            hr                                             25.60                                       28.37         110.82    Half-life        hr                                             39.45                                        42.39         107.45
  Penetration                                                      0.24                                        0.27          111.16    Lambda z         1/hr                                           0.04                                         0.04          80.86
                    MRT                                            hr                                          98.83         78.43     79.37                                                                                                                      
  T~MAX~            hr                                             8.00\*                                      2.45          30.62                                                                                                                                
  Penetration                                                      0.15                                        0.07          47.90                                                                                                                                
  ----------------- ---------------------------------------------- ------------------------------------------- ------------- --------- ---------------- ---------------------------------------------- -------------------------------------------- ------------- ---------

k01, and k10, rates for absorption and elimination processes, respectively, and accompanying half-lives (T½); AUC, area under the curve; AUC infinity, area under the curve from time zero to infinity; AUC 0 to Cn, area under the curve from time zero to the last measured time point (Cn); AUC~TAU~ , AUC (τ) for the dose interval (tau = 24 hours) for ceftiofur administered 3 times; C~MAX~, maximum drug concentration; T~MAX,~ time to maximum drug concentration; C~MIN~ , minimum drug concentration; C~AVE~ , average drug concentration; Lambda-z (λ ~Z~), terminal slope; MRT, mean residence time; penetration factor, calculated from the AUC ratios of tissue fluid/plasma; NA indicates that there was insufficient sample collection to calculate these values;

\* indicates that values are significantly different between the two formulations, P\<0.05.

Concentration of *E*. *coli* {#sec019}
----------------------------

The fecal concentration of *E*. *coli* was not different between CHCL (7.8 ± 0.25 log~10~ CFU/g) and CCFA (7.6 ± 0.35 log~10~ CFU/g) treatment groups at time 0 (P = 0.9). In the CHCL group, the mean concentration decreased by 1.7 log~10~ by 24 hours, but the change at this or any other time point was not significantly different compared to time 0 (P = 0.52). In the CCFA group, the mean concentration significantly decreased within 24 hours (5.4 + 0.38 log~10~ CFU/g, P = 0.002), and ultimately decreased by 3.4 log~10~ by 48 hours (P = 0.007). The concentration slowly increased after this point, but never returned to baseline ([Fig 2](#pone.0223378.g002){ref-type="fig"}).

![Fecal *E*. *coli* concentration over time after treatment with either ceftiofur crystalline free acid (CCFA) or ceftiofur hydrochloride (CHCL).\
Mean ± SD. \* indicates a significant difference from time 0, P ≤0.05.](pone.0223378.g002){#pone.0223378.g002}

*E*. *coli* minimum inhibitory concentration {#sec020}
--------------------------------------------

Descriptive statistics (mean, median, SD and range) for MIC values by drug and sample time are presented in [Table 2](#pone.0223378.t002){ref-type="table"}. [Table 3](#pone.0223378.t003){ref-type="table"} depicts the mean MIC estimates from multivariable models including fixed effects for drug, sample time and drug by sample time. The interaction between drug formulation and sample time was significantly (P \< 0.001) associated with MIC values, indicating that the effect of drug formulation on MIC values depended on the time point. When CCFA was administered, MIC values significantly increased at 24 hours (mean MIC = 1.32 ug/ml, 95% CI = 0.60--1.93 ug/ml) and continued to increase up to 96 hours, when MIC peaked (mean MIC = 10.68 ug/ml, 95% CI = 5.47--20.85 ug/ml), followed by a decrease in MIC values to baseline levels, and the MIC~50~ was within the wild-type distribution at 14 days after treatment. The mean MIC was significantly greater than the MIC at 0 hours from 24 hours through 168 hours after treatment ([Table 3](#pone.0223378.t003){ref-type="table"}). When CHCL was administered, MIC values peaked at 48 hours (mean MIC = 20.45 ug/ml, 95% CI = 10.29--40.63 ug/ml) and then again at 72 hours (mean MIC = 19.58 ug/ml, 95% CI = 10.03--38.24 ug/ml), followed by a steady decrease to baseline levels, and the MIC~50~ was within the wild-type distribution by 120 hours after the initial dose ([Table 3](#pone.0223378.t003){ref-type="table"} and [Fig 3](#pone.0223378.g003){ref-type="fig"}). In this group, the mean MIC was significantly greater than the MIC at 0 hours from 24 hours to 96 hours after initial treatment ([Table 3](#pone.0223378.t003){ref-type="table"}). At no time was there a significant difference between the two treatment groups at the same time point.

![Mean minimum inhibitory concentration (MIC, ± 95% CI) of ceftiofur in *E*. *coli* isolates from steers treated with ceftiofur crystalline free acid (CCFA) and ceftiofur hydrochloride (CHCL).](pone.0223378.g003){#pone.0223378.g003}

10.1371/journal.pone.0223378.t002

###### Descriptive statistics for minimum inhibitory concentration (MIC) by drug and time point.

![](pone.0223378.t002){#pone.0223378.t002g}

  MIC                                         
  ------ ------- ---- ------- ------- ------- --------------
  CCFA                                        
         0 h     48   0.46    0.50    0.13    0.25--1.00
         24 h    48   14.5    0.50    51.33   0.25--256.00
         36 h    48   13.16   0.50    38.41   0.25--256.00
         48 h    48   23.63   8.00    61.14   0.25--256.00
         60 h    \-   \-      \-      \-      \-
         72 h    48   35.58   12.00   76.26   0.50--256.00
         96 h    48   37.16   16.00   75.75   0.25--256.00
         120 h   48   23.57   8.00    61.12   0.25--256.00
         168 h   48   32.33   8.00    77.30   0.25--256.00
         240 h   \-   \-      \-      \-      \-
         336 h   48   1.05    0.50    1.84    0.25--8.00
  CHCL                                        
         0 h     48   8.75    0.50    37.03   0.25--256.00
         24 h    48   8.71    8.00    9.20    0.25--32.00
         36 h    48   12.31   16.00   8.53    0.25--32.00
         48 h    48   41.85   16.00   74.09   1.00--256.00
         60 h    48   32.52   16.00   59.70   0.25--256.00
         72 h    48   50.85   16.00   85.99   0.25--256.00
         96 h    48   51.05   8.00    93.11   0.25--256.00
         120 h   48   5.31    0.50    6.70    0.25--16.00
         168 h   48   10.47   0.50    37.10   0.25--256.00
         240 h   48   7.89    0.50    36.91   0.25--256.00
         336 h   48   2.17    0.50    4.61    0.25--16.00

CCFA = ceftiofur crystalline free acid; CHCL = ceftiofur hydrochloride; n = number of observations; SD = standard deviation.

10.1371/journal.pone.0223378.t003

###### Model-adjusted mean[\*](#t003fn004){ref-type="table-fn"}minimum inhibitory concentration (MIC) estimates, 95% confidence intervals and P-values by drug, sample time and drug by sample time.

![](pone.0223378.t003){#pone.0223378.t003g}

  Variable                                                   Mean MIC                                        95% CI mean MIC   P-value[^†^](#t003fn002){ref-type="table-fn"}
  ---------------------------------------------------------- ----------------------------------------------- ----------------- -----------------------------------------------
  Drug                                                                                                                         0.425
  CCFA                                                       NA                                              NA                
  CHCL                                                       3.53                                            1.91--6.52        
  Sample Time                                                                                                                  \<0.001
  0                                                          0.69                                            0.46--1.05        
  24                                                         1.93                                            1.19--3.14        
  36                                                         3.56                                            2.20--5.77        
  48                                                         8.98                                            5.53--14.58       
  60                                                         \-                                              \-                
  72                                                         12.88                                           7.97--20.84       
  96                                                         9.11                                            5.44--15.26       
  120                                                        2.40                                            1.39--4.12        
  168                                                        2.48                                            1.51--4.08        
  240                                                        \-                                              \-                
  336                                                        0.61                                            0.39--0.97        
  Drug x Sample Time                                                                                                           \< 0.001
  CCFA 0                                                     0.44                                            0.25--0.80        
  CCFA 24                                                    1.32                                            0.60--1.93        
  CCFA 36                                                    2.12                                            1.07--4.19        
  CCFA 48                                                    3.94                                            1.98--7.83        
  CCFA 60                                                    \-                                              \-                
  CCFA 72                                                    8.48                                            4.25--16.91       
  CCFA 96                                                    10.68                                           5.47--20.85       
  CCFA 120                                                   3.67                                            1.67--8.04        
  CCFA 168                                                   4.24                                            2.01--8.96        
  CCFA 240                                                   \-                                              \-                
  CCFA 336                                                   0.61                                            0.32--1.70        
  CHCL 0                                                     1.08                                            0.60--1.93        
  CHCL 24                                                    2.83                                            1.42--5.62        
  CHCL 36                                                    5.99                                            3.03--11.84       
  CHCL 48                                                    20.45                                           10.29--40.63      
  CHCL 60                                                    14.89                                           7.46--29.70       
  CHCL 72                                                    19.58                                           10.03--38.24      
  CHCL 96                                                    7.77                                            3.55--20.85       
  CHCL 120                                                   1.57                                            0.74--3.31        
  CHCL 168                                                   1.46                                            0.76--2.79        
  CHCL 240                                                   0.90                                            0.48--1.70        
  CHCL 336                                                   0.61                                            0.32--1.18        
  Significant contrasts for Drug x Sample Time interaction                                                                     
  Contrast                                                   P-value[^‡^](#t003fn003){ref-type="table-fn"}                     
  CCFA 0 vs CCFA 24                                          0.009                                                             
  CCFA 0 vs CCFA 36                                          \<0.001                                                           
  CCFA 0 vs CCFA 48                                          \<0.001                                                           
  CCFA 0 vs CCFA 72                                          \<0.001                                                           
  CCFA 0 vs CCFA 96                                          \<0.001                                                           
  CCFA 0 vs CCFA 120                                         \<0.001                                                           
  CCFA 0 vs CCFA 168                                         \<0.001                                                           
  CHCL 0 vs CHCL 24                                          0.041                                                             
  CHCL 0 vs CHCL 36                                          \<0.001                                                           
  CHCL 0 vs CHCL 48                                          \<0.001                                                           
  CHCL 0 vs CHCL 60                                          \<0.001                                                           
  CHCL 0 vs CHCL 72                                          \<0.001                                                           
  CHCL 0 vs CHCL 96                                          \<0.001                                                           

CCFA = ceftiofur crystalline free acid; CHCL = ceftiofur hydrochloride; NA = Not available.

† Overall significance test (F-test) .

^‡^ P-values represent Tukey-Kramer's adjustment for multiple comparisons.

\*These estimates are from GLMM models including drug, sample time and a two-way. interaction between drug and sample time, after accounting for isolates nested within samples and repeated measures at the animal level.

Alterations in the fecal microbiota {#sec021}
-----------------------------------

As seen in [Fig 4](#pone.0223378.g004){ref-type="fig"}, there was a shift in the microbial communities after treatment with either CHCL or CCFA. This shift appears to be slower, but more pronounced and persistent in the steers treated with CCFA. Yet, in neither group does the community return to its initial structure at 2 weeks after treatment. These shifts are largely due to a reduction in Firmicutes and an increase in Bacteroidetes ([Fig 5](#pone.0223378.g005){ref-type="fig"}). The Archea, primarily composed of *Methanobrevibacter*, follow a similar trajectory of initial decline with a slow, incomplete recovery over time ([Fig 6](#pone.0223378.g006){ref-type="fig"}).

![Principal coordinate analysis of the microbial communities in each steer over time.](pone.0223378.g004){#pone.0223378.g004}

![The relative abundance of each phylum present in steers after treatment with either ceftiofur hydrochloride (CHCL) or ceftiofur crystalline free acid (CCFA).\
Each bar represents an individual calf.](pone.0223378.g005){#pone.0223378.g005}

![Changes in the proportion of *Methanobrevibacter* over time in both the ceftiofur hydrochloride (CHCL) and ceftiofur crystalline free acid (CCFA) groups.](pone.0223378.g006){#pone.0223378.g006}

Discussion {#sec022}
==========

Because of its broad spectrum of activity, short slaughter withdrawal time, and zero milk withdrawal time, ceftiofur is one of the most commonly used antimicrobials in cattle in the United States. As it is available in multiple formulations for use in cattle, we investigated the gastrointestinal PK of two different formulations and their impact on enteric bacteria to determine if selection of one formulation over another could be a viable means to mitigate selection of AMR enteric bacteria.

Because of the slow release of ceftiofur from CCFA, the maximum concentrations (C~MAX~) of ceftiofur and metabolites in the plasma were significantly lower than from injection of CHCL ([Fig 1](#pone.0223378.g001){ref-type="fig"}). The slow release formulation also impacted the plasma T~MAX~ as concentrations from CCFA peaked later than that of CHCL, but the prolonged half-life significantly increased the plasma AUC. These findings are similar to a comparative PK study in neonatal calves \[[@pone.0223378.ref035]\]. ISF fluid concentrations for CHCL were similar to those of ceftiofur sodium \[[@pone.0223378.ref015]\], and reflects the high protein binding (93%) of the metabolite measured in our previous study \[[@pone.0223378.ref022]\]. However, the ISF concentrations after CCFA injection were much higher. This likely occurred because of a longer time for equilibration between plasma and interstitial tissue fluid for CCFA. This also produced longer persistence of ceftiofur and its metabolites in intestinal fluids. These observations are consistent with previous evidence from tissue cages that showed that with a prolonged half-life, penetration into interstitial fluids can increase due to the additional time for diffusion \[[@pone.0223378.ref036],[@pone.0223378.ref037]\].

The concentrations measured in the GIT were lower than previously reported \[[@pone.0223378.ref015]\], which may be due to differences in formulation, but we cannot confirm this without additional study. In the previous study, steers were administered ceftiofur sodium, compared to CHCL and CCFA that were administered in this study. Interestingly, there minimal significant differences in the GI PK parameters between the two formulations in this study. This may be explained by the large variability between calves and the relatively small numbers in each group. The penetration into the ileum and colon was similar for both formulations, yet the numerical differences in C~MAX~ and half-life suggest prolonged, low drug concentrations in the ileum and colon of steers receiving CCFA. Because there were differences in the effect on *E*. *coli* and the microbiome, it suggests to us that this property produced clinically relevant differences in the GI PK parameters. Further, these concentrations were dramatically lower than predicted through mathematical models \[[@pone.0223378.ref038]\], demonstrating the need for empirical data. Here, the intestinal concentrations were above MIC 90 for *E*. *coli* after CHCL administration, but only briefly. For CCFA, concentrations never reached the MIC 90, but the concentrations were above the MIC for the most susceptible wild-type strains.

According to EUCAST ([www.EUCAST.org](http://www.eucast.org/)) wild-type *E*. *coli* have ceftiofur MIC values that range from 0.12--1.0 μg/ml; thus, the more susceptible strains were exposed to ceftiofur and metabolites longer after injection of CCFA compared to CHCL. This may explain why CCFA had a more significant impact on the concentration of *E*. *coli* in the feces compared to CHCL. As ceftiofur is a time-dependent drug, one can speculate that longer drug exposure of *E*. *coli* in the GIT produced a greater reduction in the *E*. *coli* populations in spite of the low drug concentrations. This reduction is similar to what has been described previously in feedlot cattle \[[@pone.0223378.ref010],[@pone.0223378.ref039]\]. CHCL peak concentrations in GIT were higher than CCFA, but with a much shorter half-life. As demonstrated in our previous study with ceftiofur sodium and by others, at this high concentration ceftiofur appears to be rapidly degraded by enteric bacteria, which shortens the exposure time \[[@pone.0223378.ref015],[@pone.0223378.ref040]\]. This may mitigate the impact of the drug on the concentration of *E*. *coli* in the feces in our study. In a previous study of dairy cattle treated daily for 5 days with ceftiofur, there was a significant decrease in fecal shedding of *E*. *coli* by these cows \[[@pone.0223378.ref041]\]. It is unclear in that study if the cows received CHCL or ceftiofur sodium. We found higher concentrations of ceftiofur and metabolites in the intestine after injections of ceftiofur sodium \[[@pone.0223378.ref015]\] compared to CHCL in this study, which could explain this difference.

The relative impact of the two formulations on microbiota of the steers was similar to their impact on *E*. *coli*. CCFA appears to have a more significant and prolonged effect on the bacterial communities overall. Specifically, there is a greater reduction in Firmicutes and increase in Bacteroidetes in steers treated with CCFA compared to CHCL. The clinical impact of these changes is undetermined, because the normal microbiota is undefined in this population. Both phyla are commonly found in the feces of adult cattle, with Firmicutes commonly being the predominate phylum \[[@pone.0223378.ref006],[@pone.0223378.ref042]\]. Most studies of *Methanobrevibacter* have shown that it is the most common methanogen in the rumen of cattle \[[@pone.0223378.ref043],[@pone.0223378.ref044]\], but its role in the fecal microbiota is unclear. Interestingly, reducing this organism could reduce methane production in treated animals and improve feed efficiency \[[@pone.0223378.ref043]\]. It is not known if this reduction in *Methanobrevibacter* is found in the rumen as well. Antimicrobial concentrations in the rumen after injection of these formulations have not been reported.

Though CCFA had a greater impact on the concentration of *E*. *coli* and the microbiome, the changes in *E*. *coli* ceftiofur MIC depended on the time of sampling, with no evidence of statistical differences in MIC between treatments at the same time point. Over time, the increase in mean MIC was greater in the CHCL group than in CCFA. The increase in mean MIC persisted longer for CCFA than CHCL (168 hours vs 96 hours), which is not surprising as the drug in intestinal fluids persisted longer from CCFA than CHCL ([Fig 1](#pone.0223378.g001){ref-type="fig"}). Nonetheless, in both groups, the MIC values returned to baseline prior to the end of meat residue withdrawal time for each drug, suggesting that persistence of *E*. *coli* with an MIC above the wild-type cutoff ([www.EUCAST.org](http://www.eucast.org/)) in an animal at slaughter would be relatively unlikely. These findings are similar to previous results in dairy cattle \[[@pone.0223378.ref013],[@pone.0223378.ref041]\] and beef cattle \[[@pone.0223378.ref039]\] demonstrating short-lived resistance to third-generation cephalosporins. Resistance to third-generation cephalosporin among *E*. *coli* isolates found in cattle at slaughter \[[@pone.0223378.ref045]\] is likely caused by other factors, rather than single uses of ceftiofur in cattle. Two studies in feedlot cattle have demonstrated a significant increase in resistant fecal *E*. *coli* \[[@pone.0223378.ref010]\] and carriage of cephalosporin resistance genes \[[@pone.0223378.ref011]\] in association with combined treatment with CCFA and oral chlortetracycline. This suggests that co-selection of resistance mechanisms may play a greater role in maintaining these resistance elements within the fecal microbiota once the initial selection pressure associated with ceftiofur administration has waned.

While this is the first study to associate intestinal pharmacokinetics with changes in AMR in enteric *E*. *coli* and with changes in the microbiome, our conclusions are limited by the size of the study. The sample size was determined based on the numbers needed to assess the pharmacokinetics of the drugs and this may not have been adequate for the microbial analyses. When analyzing MIC values, challenges in terms of the nature of the distribution of these data, which are not truly continuous and may be truncated, arise. Although several family distributions and transformations of the outcome were attempted, the chosen logarithmic transformation and statistical model provided a better fit by improving the skewness of the underlying distribution while accounting for the design structure (lack of independence due to multiple isolates per sample and repeated measures) of the study. Statistical comparisons of the changes in the microbiome are limited due to the high variability and small sample size. Our observations on antimicrobial resistance are limited to the changes in *E*. *coli*. Although this organism is commonly used as an indicator organism, it is unclear how generalizable these findings are to changes in the susceptibility profile of other enteric bacteria.

In conclusion, the relatively long persistence of active drug in the intestine of cattle treated with CCFA has a significant and prolonged effect on the concentration of *E*. *coli* in the feces and the microbiome. Repeated injections of CHCL did not have the same effect on fecal *E*. *coli* concentrations or the microbiome. CCFA increased the mean MIC of ceftiofur in fecal *E*. *coli* for a longer period of time, but this returned to baseline with two weeks after treatment.

This research was supported by work performed by The University of Michigan Microbial Systems Molecular Biology Laboratory. The authors thank Delta R. Dise of the NC State University Clinical Pharmacology Laboratory for her expertise performing the drug assays.

10.1371/journal.pone.0223378.r001

Decision Letter 0

Mühldorfer

Kristin

Academic Editor

© 2019 Kristin Mühldorfer

2019

Kristin Mühldorfer

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1 Jul 2019

PONE-D-19-14785

Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers

PLOS ONE

Dear Dr. Foster,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. The manuscript has been reviewed by two experts in the field and they have raised concerns because of the experimental design, statistical analyses and the conclusions drawn from the results. They also indicated discrepancies between text and tables, while the contents of the tables should be precise. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Aug 15 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Kristin Mühldorfer

Academic Editor

PLOS ONE

**Journal Requirements:**

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In your Methods, please state the volume of the blood samples collected for use in your study.

3\. In your Methods section, please include a comment about the state of the animals following this research. Were they euthanized or housed for use in further research? If any animals were sacrificed by the authors, please include the method of euthanasia and describe any efforts that were undertaken to reduce animal suffering.

4\. Thank you for stating the following in the Competing Interests section:

\"I have read the journal\'s policy and the authors of this manuscript have the following competing interests: DMF has received research support from Zoetis. MGP has received gifts, honoraria, consulting fees, and research support from Zoetis, the manufacturer of ceftiofur.  \"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

5\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Congratulations to the authors for this well planned animal study, with linkable effects of administration of ceftiofur in two formulations (Excede and Excenel) on amount and MIC of E. coli and impact on other microbiota in colon, combined with PK data at different sites (serum, ISF and Intestinal fluid) at identical time-points.

Some findings are contradictory with each other or with other, older studies.

The ISF concentrations after CCFA injection were much higher. This likely occurred because of a longer time for equilibration between plasma and interstitial tissue fluid for CCFA. But why is the half-live in ISF for CCFA much shorter than for CHCL? This is also contradictory to the next statement, that this longer time for equilibration is responsible for a longer persistence (implying and also showing longer half-lives) in the intestinal fluids. Why isn't this persistence of CCFA found in ISF?

With the repetitive injections during three days of CHCL, with three times relatively high concentrations, one could expect to find E. coli with higher MIC's. But this finding isn't in line with the findings of Goessens et.al, Journal of Antimicrobial Chemotherapy (2007) 59, 507-- 516. They showed that selection of resistant Enterobacter cloacae was induced by a regimen with more continuous administration of ceftazidime (every 6 hrs, to be compared with the continuous release of CCFA) as compared to 4 times higher dose every 24 hrs (comparable with the CHCL regimen). This is attributable to the period in the mutant selection window. Goessens et al did determine the mutant preventive concentration (MPC), which was 16 mg/L for E. cloacae. Looking at the concentrations attained with the (authorized) dosage regimens of both ceftiofur products, and assuming that the MPC for E. coli won't be lower than 16 mg/L, one must conclude that both regimens (3 days 2.2 mg/kg and once 6.6 mg/kg) are prone to select during therapy, and therefor no preferred regimen can be determined. Knowing the MIC and the MPC (of ceftiofur) for E. coli, and adjusting the dosing regimen to these MIC and MPC, combined with the finding that the concentrations found in ISF and intestinal fluids for ceftiofur are not very different from the levels in plasma, could change the outcomes in selection of bacteria with high MICs.

L 43 \...is one of the most common antimicrobials\...: please be more specific: might be applicable for the USA (but not in all countries worldwide)

L 239 Schloss SOP: please add a reference; my question: are all specifications mentioned here divergent form the SOP?

L 247 \...removed using the default consensus removal method\....: Add ref and specify

L 253 \...Holm-Sidak method for comparison of individual time points to time 0..:. Add ref

L 270 \...The Tukey-Kramer procedure\...: Add ref

L 285/table1:

specify AUC in plasma

CCFA ISF: AUCinf \< AUV 0 to cn seems impossible? Half-live=17.81 hr vs 44.94 hr of CHCL (but Lambda z is same magnitude 0.5 and 0.4?), and still AUC CCFA \> AUC CHCL?

CCFA ileum: MRT is smaller than CHCL ileum?

Legend table 1 is incomplete: MRT

L 365 \...ceftiofur is one of the most commonly used antimicrobials in cattle\...: add in USA

Reviewer \#2: Dear Authors,

This manuscript investigates "Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers". The topic of the study is in line with those dealt by the journal and also the organization of manuscript is in line with instructions of PLOS ONE. It is thought that the data obtained from this study, will contribute to veterinary practice. With this approach, this study is considered as an original and valuable research. I find the authors have made a good study design and I would like to read this paper on PLOS ONE, but have multiple suggestions to consider. It is determined that the part of this article about MIK is written in a very descriptive and orderly manner. However, there are deficiencies in the information written about pharmacokinetics. You need to be more specific about pharmacokinetic parameters as these could affect your outcome.

Introduction

Line 43-44: Although Ceftiofur has been approved for the treatment of respiratory diseases, you should not forget that it is also used in the treatment of Ecoli-associated diarrhea in calves. I think you should be more informative instead of just saying that the drugs are administered for treatment of respiratory disease.

Materials and methods

Line 88-91 - Your pharmacokinetic design is not explained. The naming of your study design implies that all the calves were enrolled simultaneously. Please be more descriptive to allow the reader to understand how your study design. Cross-over or parallel pharmacokinetic design???

Line 98- Blood samples were collected in which tubes (EDTA or Li-heparin)? Provide tube information.

Line 99-101- You need to be more specific about blood, gastrointestinal and intestinal fluid sample point to make the meaning clear to the readers. For example; at 0 (pre-treatment), 5, 10, 15, 20, 25, 30, and 45 min and 36 h post-dosing. Which sampling times you have used for pharmacokinetic?

Line 113-114- \"The calves received 2 mg/kg of flunixin meglumine intravenously prior to surgery and 24 hours after surgery\". Could this drug have caused a change in the pharmacokinetic profile of ceftiofur? What impact this might have had on data interpretation, if any?

Line 115 and 127- You need to be more specific about predetermined time points.

Line 150- Are you used the WinNonlin program for statistical difference. I don't understand..

Line 251- Did you compare the pharmacokinetic parameters statistically?

Results

Line 274- Pharmacokinetic modelling- Did you write your results here without any statistical comparison?

Discussion: Discussion of the study is not sufficient: the pharmacokinetic parameters were ignored. After the statistical analysis, I suggest re-evaluation of the relevant parts of the pharmacokinetic parameters.

Line 364-367- This line is like a repetition of the sentences in Line 43-44. I suggest you to combine these in introduction. Since your hypothesis is especially about the efficacy of ceftiofur in intestinal flora, you can instead add articles about the use of ceftiofur in calves with diarrhea. For this reason, I suggest below articles could be added to the discussion section of this study.

1\. Constable P. D. 2009. Treatment of calf diarrhea: antimicrobial and ancillary treatments. Vet. Clin. North Am. Food Anim. Pract. 25: 101--120.

2\. Feray ALTAN, Kamil UNEY, Ayse ER, Gul CETIN, Burak DIK, Enver YAZAR, and Muammer ELMAS. Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy. J Vet Med Sci. 2017 Jul; 79(7): 1245--1252.

Line 367-368- This information is new and should be moved to the introduction section in line 54.

Line 370-372- This line is like a repetition of the sentences in Line 54-60. I suggest you to delete in discussion.

Line 372-374- I think it would be more appropriate for you to discuss this sentence in a different way rather than repeating what you have written in introduction section.

Line 375-377- You can\'t tell these without any statistical analysis. Also the table you have presented is so confused that I cannot reach this conclusion by looking at your table.

Line 376- Cmax of CCFA in ISF was not lower than CCFA. Please be carefully. The data you type in the table should be consistent with what you type in the text.

Line 379-384- You were stated "The ISF concentrations after CCFA injection were much higher. This likely occurred because of a longer time for equilibration between plasma and interstitial tissue fluid for CCFA. This also produced longer persistence of ceftiofur and its metabolites in intestinal fluids." You have indicated in your table that the half-life of CCFA is shorter than CHLC in ISF. Can you explain why the half-life and the concentration of CHLC is long and low in ISF.

Line 385-409- Ceftiofur are beta-lactam antimicrobial drugs. Activity of beta-lactams is time-dependent kill characteristics, and the most useful and predictable parameter for optimal bactericidal activity is %T\>MIC. Use this parameter to give information about the susceptible bacteria for ceftiofur. You can't this say it through MIC 90 and concentration. You should determine to %T\>MIC for susceptible bacteria.I suggest below article could be added

Turnidge, J. D. (1998). The pharmacodynamics of beta‐lactams. Clinical Infectious Diseases, 27, 10--12.

Table 1. I think you need more explanation in this table. Why did you not compare the differences in plasma concentrations?

Figure 5. Calves?????

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Ingeborg M. van Geijlswijk

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0223378.r002

Author response to Decision Letter 0

19 Aug 2019

Thank you to the editors and reviewers for their helpful comments. We have attempted to address all of the stated concerns or explain our rationale for where we disagree. The line numbers listed here in our responses correspond to the version of the manuscript without tracked changes.

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

AU: Our apologies for these errors. We have reviewed the guidelines and corrected the manuscript throughout.

2\. In your Methods, please state the volume of the blood samples collected for use in your study.

AU: This has been added to Line 106.

3\. In your Methods section, please include a comment about the state of the animals following this research. Were they euthanized or housed for use in further research? If any animals were sacrificed by the authors, please include the method of euthanasia and describe any efforts that were undertaken to reduce animal suffering.

AU: The following statement has been added to lines 102-103. "At the conclusion of the study and observation of the appropriate meat withdrawal time, all ultrafiltration probes and catheters were removed, and the steers were sold.

4\. Thank you for stating the following in the Competing Interests section:

\"I have read the journal\'s policy and the authors of this manuscript have the following competing interests: DMF has received research support from Zoetis. MGP has received gifts, honoraria, consulting fees, and research support from Zoetis, the manufacturer of ceftiofur. \"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

AU: Any competing interests do not affect our adherence to PLOS ONE policies on data sharing. This information is now included in our new cover letter.

5\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

AU: The data has now been uploaded to NCBI Bioproject. The ID is PRJNA560079.

Comments to the Author

Reviewer \#1: Congratulations to the authors for this well planned animal study, with linkable effects of administration of ceftiofur in two formulations (Excede and Excenel) on amount and MIC of E. coli and impact on other microbiota in colon, combined with PK data at different sites (serum, ISF and Intestinal fluid) at identical time-points.

Some findings are contradictory with each other or with other, older studies.

The ISF concentrations after CCFA injection were much higher. This likely occurred because of a longer time for equilibration between plasma and interstitial tissue fluid for CCFA. But why is the half-live in ISF for CCFA much shorter than for CHCL? This is also contradictory to the next statement, that this longer time for equilibration is responsible for a longer persistence (implying and also showing longer half-lives) in the intestinal fluids. Why isn't this persistence of CCFA found in ISF?

AU: We appreciate the reviewer's comments and observations. We agree that ISF concentrations were probably higher from CCFA compared to the other formulation because of longer time for equilibrium for the slow-release product. The reviewer also pointed out discrepancies in the half-life between formulations in the ISF fluid. This occurred as an artifact of the analysis and was overlooked earlier. Occasionally the interstitial probes did not collect enough fluid, or became plugged or kinked and failed. Therefore, we sometimes had only sparse points for which to calculate the half-life. For the measurement of a mean half-life value for ISF after administration of ceftiofur hydrochloride, upon further review of our data, we note that the mean was heavily skewed by two animals that had very long half-lives and the coefficient of variation for this parameter was very large. In retrospect, we should not have included the half-life from these individuals. Therefore, we have modified our data to eliminate these animals from the analysis. See our revised tables. We thank the reviewer for this careful observation.

With the repetitive injections during three days of CHCL, with three times relatively high concentrations, one could expect to find E. coli with higher MIC's. But this finding isn't in line with the findings of Goessens et.al, Journal of Antimicrobial Chemotherapy (2007) 59, 507-- 516. They showed that selection of resistant Enterobacter cloacae was induced by a regimen with more continuous administration of ceftazidime (every 6 hrs, to be compared with the continuous release of CCFA) as compared to 4 times higher dose every 24 hrs (comparable with the CHCL regimen). This is attributable to the period in the mutant selection window. Goessens et al did determine the mutant preventive concentration (MPC), which was 16 mg/L for E. cloacae. Looking at the concentrations attained with the (authorized) dosage regimens of both ceftiofur products, and assuming that the MPC for E. coli won't be lower than 16 mg/L, one must conclude that both regimens (3 days 2.2 mg/kg and once 6.6 mg/kg) are prone to select during therapy, and therefor no preferred regimen can be determined. Knowing the MIC and the MPC (of ceftiofur) for E. coli, and adjusting the dosing regimen to these MIC and MPC, combined with the finding that the concentrations found in ISF and intestinal fluids for ceftiofur are not very different from the levels in plasma, could change the outcomes in selection of bacteria with high MICs.

AU: While the study by Goessens et al. is a robust evaluation of the different dosing regimens of ceftazidime, drawing comparisons from that study to ours is difficult. Differences in PK between cattle and rodents are likely significant, and their associations between plasma drug concentrations and selection for resistance may be very different than associations between drug concentrations in the GI tract and resistance. It is unclear from their study how closely the GI concentrations mirrored the plasma concentrations, and it is probably not appropriate to assume that ceftazidime concentrations in rodents is similar to our data with ceftiofur in cattle. Further, dosing every 6 hours may achieve a relatively constant drug concentration, but we would expect that this would be higher than that achieved by a slow release formulation like CCFA.

One of the explanations for the findings offered in the comments is the time that concentrations were in the "Mutant Selection Window". However, we do not believe that a mutant selection window (or mutant selection concentration) exists for cephalosporins against Enterobacteriaceae. Resistance to the cephalosporins is usually conferred by production of beta-lactamase. We believe that bacteria acquire the ability to produce beta-lactamases via transfer of genetic elements, not through spontaneous mutations in treated animals. Therefore, we do not believe a mutant prevention concentration (or window) can be defined for ceftiofur against E. coli. Our view on this is shared by others (eg, Smith et al. Stretching the mutant prevention concentration (MPC) beyond its limits. Journal of Antimicrobial Chemotherapy. 2003 Jun 1;51(6):1323-5.).

L 43 \...is one of the most common antimicrobials\...: please be more specific: might be applicable for the USA (but not in all countries worldwide)

AU: "in the United States" has been added to line 48.

L 239 Schloss SOP: please add a reference; my question: are all specifications mentioned here divergent form the SOP?

AU: Reference 25 in line 252 is added to clarify that this SOP is contained in the supplemental data of this reference. The specifications in this section are included in this SOP except where noted with references 24 and 26.

L 247 \...removed using the default consensus removal method\....: Add ref and specify

AU: This has now been appropriately referenced.

L 253 \...Holm-Sidak method for comparison of individual time points to time 0..:. Add ref

AU: References have been added.

L 270 \...The Tukey-Kramer procedure\...: Add ref

AU: References have been added.

L 285/table1:

specify AUC in plasma

AU: This has been added to line 297 to clarify that the penetration is based on plasma AUC, and is a term that we defined as the ratio of the AUC of the tissue (ISF, intestinal fluids) to the AUC of plasma.

CCFA ISF: AUCinf \< AUV 0 to cn seems impossible? Half-live=17.81 hr vs 44.94 hr of CHCL (but Lambda z is same magnitude 0.5 and 0.4?), and still AUC CCFA \> AUC CHCL? CCFA ileum: MRT is smaller than CHCL ileum?

AU: We thank the reviewer for picking this up. The reviewer is correct. This is not possible. The half-life estimates for the ISF was skewed by a few outliers and we have modified the tables to eliminate this value. The reviewer is correct that AUC 0 to Cn should not be greater than AUC 0 to infinity. This was due to an error in which some animals were included in the mean calculation, even though the samples were incomplete and should not have been included. We have revised our tables to fix these errors. We apologize for not reviewing this more closely prior to manuscript submission.

Legend table 1 is incomplete: MRT

AU: Thank you for catching this oversight. It has been added to line 309.

L 365 \...ceftiofur is one of the most commonly used antimicrobials in cattle\...: add in USA

AU: This has been added to line 378-379.

Reviewer \#2: Dear Authors,

This manuscript investigates "Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers". The topic of the study is in line with those dealt by the journal and also the organization of manuscript is in line with instructions of PLOS ONE. It is thought that the data obtained from this study, will contribute to veterinary practice. With this approach, this study is considered as an original and valuable research. I find the authors have made a good study design and I would like to read this paper on PLOS ONE, but have multiple suggestions to consider. It is determined that the part of this article about MIK is written in a very descriptive and orderly manner. However, there are deficiencies in the information written about pharmacokinetics. You need to be more specific about pharmacokinetic parameters as these could affect your outcome.

Introduction

Line 43-44: Although Ceftiofur has been approved for the treatment of respiratory diseases, you should not forget that it is also used in the treatment of Ecoli-associated diarrhea in calves. I think you should be more informative instead of just saying that the drugs are administered for treatment of respiratory disease.

AU: Additional information in lines 48-50 has been added to clarify that ceftiofur is also used to treat enteric disease.

Materials and methods

Line 88-91 - Your pharmacokinetic design is not explained. The naming of your study design implies that all the calves were enrolled simultaneously. Please be more descriptive to allow the reader to understand how your study design. Cross-over or parallel pharmacokinetic design???

AU: Lines 97-98 have been edited to clarify that it was parallel study was used. Use of a crossover design would have interfered with the interpretation of the microbiological results.

Line 98- Blood samples were collected in which tubes (EDTA or Li-heparin)? Provide tube information.

AU: Lithium-heparin tubes were used and this is added to line 106-107.

Line 99-101- You need to be more specific about blood, gastrointestinal and intestinal fluid sample point to make the meaning clear to the readers. For example; at 0 (pre-treatment), 5, 10, 15, 20, 25, 30, and 45 min and 36 h post-dosing. Which sampling times you have used for pharmacokinetic?

AU: This has been added to lines 109-111 and 137-139. All timepoints were included in the pharmacokinetic modeling.

Line 113-114- \"The calves received 2 mg/kg of flunixin meglumine intravenously prior to surgery and 24 hours after surgery\". Could this drug have caused a change in the pharmacokinetic profile of ceftiofur? What impact this might have had on data interpretation, if any?

AU: Without undue additional study, we cannot determine the influence that flunixin may have on the pharmacokinetics of ceftiofur. We considered this, but decided not to entertain any speculation on a proposed effect. In addition, there is no evidence of drug interactions when ceftiofur and flunixin are administered in cattle (Gorden et al., J Vet Pharmacol Ther. 2018; 41 (1):76-82). This clarification and reference have been added to lines 124-125.

Line 115 and 127- You need to be more specific about predetermined time points.

AU: This is now included in lines 137-139.

Line 150- Are you used the WinNonlin program for statistical difference. I don't understand.

AU: This has been removed and a description of the statistical analysis of the PK parameters has been added to line 265-268.

Line 251- Did you compare the pharmacokinetic parameters statistically?

AU: This has been added to line 265-268.

Results

Line 274- Pharmacokinetic modelling- Did you write your results here without any statistical comparison?

AU: Asterisks have been added to Table 1 to indicate differences based on statistical analysis. The results portion has been edited to reflect these differences.

Discussion: Discussion of the study is not sufficient: the pharmacokinetic parameters were ignored. After the statistical analysis, I suggest re-evaluation of the relevant parts of the pharmacokinetic parameters.

AU: We thank the reviewer for this suggestion. We have added more to the discussion (primarily in lines 383-407) to satisfy the reviewer's concern.

Line 364-367- This line is like a repetition of the sentences in Line 43-44. I suggest you to combine these in introduction.

AU: These have been condensed as suggested.

Since your hypothesis is especially about the efficacy of ceftiofur in intestinal flora, you can instead add articles about the use of ceftiofur in calves with diarrhea. For this reason, I suggest below articles could be added to the discussion section of this study.

1\. Constable P. D. 2009. Treatment of calf diarrhea: antimicrobial and ancillary treatments. Vet. Clin. North Am. Food Anim. Pract. 25: 101--120.

2\. Feray ALTAN, Kamil UNEY, Ayse ER, Gul CETIN, Burak DIK, Enver YAZAR, and Muammer ELMAS. Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy. J Vet Med Sci. 2017 Jul; 79(7): 1245--1252.

AU: While there is certainly the possibility that studies like ours could be used to investigate the efficacy of various antimicrobials on enteric pathogens for the treatment of diarrheal disease, our focus is on the impact GI tract drug concentrations on normal enteric bacteria to understand the effect of formulation and dosing on selection AMR bacteria and disruption of the microbiome. As our study was not designed to assess treatment efficacy, we believe that extrapolating our findings to include this information would be an inappropriate over interpretation of our findings and unnecessarily confuse the readers.

Line 367-368- This information is new and should be moved to the introduction section in line 54.

AU: This has been moved as suggested.

Line 370-372- This line is like a repetition of the sentences in Line 54-60. I suggest you to delete in discussion.

AU: These have been condensed as suggested.

Line 372-374- I think it would be more appropriate for you to discuss this sentence in a different way rather than repeating what you have written in introduction section.

AU: This has now been revised and is in lines 379-382.

Line 375-377- You can\'t tell these without any statistical analysis. Also the table you have presented is so confused that I cannot reach this conclusion by looking at your table.

AU: Thank you for this suggestion. This section has been edited to reflect the statistical analysis. We will modify the tables to attempt to make them less confusing. We have added asterisks to signify significant differences and corrected the ISF values.

Line 376- Cmax of CCFA in ISF was not lower than CCFA. Please be carefully. The data you type in the table should be consistent with what you type in the text.

AU: You are correct. This error has been corrected in line 384.

Line 379-384- You were stated "The ISF concentrations after CCFA injection were much higher. This likely occurred because of a longer time for equilibration between plasma and interstitial tissue fluid for CCFA. This also produced longer persistence of ceftiofur and its metabolites in intestinal fluids." You have indicated in your table that the half-life of CCFA is shorter than CHLC in ISF. Can you explain why the half-life and the concentration of CHLC is long and low in ISF.

AU: We made an error in our calculation of the ISF parameters in our original submission. We apologize for this oversight. As we noted in response to Reviewer \#1, this has been corrected in the tables.

Line 385-409- Ceftiofur are beta-lactam antimicrobial drugs. Activity of beta-lactams is time-dependent kill characteristics, and the most useful and predictable parameter for optimal bactericidal activity is %T\>MIC. Use this parameter to give information about the susceptible bacteria for ceftiofur. You can't this say it through MIC 90 and concentration. You should determine to %T\>MIC for susceptible bacteria.I suggest below article could be added

Turnidge, J. D. (1998). The pharmacodynamics of beta‐lactams. Clinical Infectious Diseases, 27, 10--12.

AU: Yes, we are familiar with Dr. Turnidge's work. We can indeed calculate T\>MIC for the wild-type distribution of MIC for E. coli. However, as we have discussed, because of low MIC values for E. coli, the T\>MIC was sufficiently long during the dosing interval to achieve inhibition.

Table 1. I think you need more explanation in this table. Why did you not compare the differences in plasma concentrations?

AU: Statistical comparisons between the two drugs in the various compartments have been added.

Figure 5. Calves?????

AU: Each bar represents and individual calf. This has been added to the figure legend.
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3 Sep 2019

\[EXSCINDED\]

PONE-D-19-14785R1

Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers

PLOS ONE

Dear Dr. Foster,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Reviewer 2 indicates that important information is still missing from the pharmacokinetic analysis and that the differences in the results from parameters investigated in plasma needs to be discussed. Therefore, we invite you to submit a revised version of the manuscript that carefully addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Oct 18 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Kristin Mühldorfer

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: There are still a lack of information on pharmacokinetics. You need to be more specific about pharmacokinetic parameters as these could affect your outcome. You compared the differences in only plasma concentrations. Why did you not compare the differences in other pharmacokinetic parameters? The Tmax and AUC of CCFA in plasma were difference than CHCL in plasma. Additionally, the Cmax of CCFA in plasma is lower than of CHCL in plasma. The t1/2λz CCFA in plasma was longer than CHCL in plasma. Could you suggest some reasons?

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0223378.r004

Author response to Decision Letter 1

17 Sep 2019

Thank you to the editors and reviewers for their helpful comments. We have attempted to address all of the stated concerns. The line numbers listed here in our responses correspond to the version of the manuscript without tracked changes.

Reviewer \#2: There are still a lack of information on pharmacokinetics. You need to be more specific about pharmacokinetic parameters as these could affect your outcome. You compared the differences in only plasma concentrations. Why did you not compare the differences in other pharmacokinetic parameters? The Tmax and AUC of CCFA in plasma were difference than CHCL in plasma. Additionally, the Cmax of CCFA in plasma is lower than of CHCL in plasma. The t1/2λz CCFA in plasma was longer than CHCL in plasma. Could you suggest some reasons?

AU: Our apologies that this was not more clearly stated, but we have compared the PK parameters in all the different matrices and highlighted those in Table 1 that were significantly different. In lines 291-298, we have expanded our description the observed differences in the PK parameters and have added information in lines 387-390 along with a reference highlighting the impact of the slow-release formulation of CCFA.
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Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers

PONE-D-19-14785R2

Dear Dr. Foster,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Few additional Editor comments are listed below and within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.
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